Almost half the active ingredients on FDA’s list of off-patent, off-exclusivity drugs that lack generic competition involve complexities requiring agency consultation and action before an abbreviated new drug application (ANDA) is even submitted.
Of 267 drug products, 121 (45%) involve “potential legal, regulatory, or scientific issues which should be addressed with the agency...




